Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MiNK 215

Next Previous
X
Search
Drug Profile

MiNK 215

Alternative Names: Allo-FAP-CAR-iNKT-MiNK Therapeutics; FAP-CAR-iNKT; MiNK-215; Stromal CAR iNKT - Agenus; Stromal Target-CAR-iNKT-MiNK Therapeutics; Stromal-CAR-iNKT

Latest Information Update: 15 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Agenus
  • Developer MiNK Therapeutics
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies; NKT cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer T cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 08 Oct 2024 MiNK Therapeutics enters into a research collaboration agreement with Autonomous Therapeutics to leverage precision encrypted RNA™ technology and MiNK’s innovative iNKT cell therapies, MiNK 215 and agenT 797 for the treatment of metastatic tumours
  • 08 Oct 2024 MiNK Therapeutics in collaboration with Autonomous Therapeutics plans a phase I trial for Solid tumours (Second-line therapy or greater, Combination therapy, Metastatic disease) (Parenteral)
  • 13 Aug 2024 MiNK Therapeutics plans to file an IND application for Solid tumours in early 2025

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top